Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial.
about
Angiotensin receptor blockers for heart failureMedical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancerMedical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancerDifferential clinical profile of candesartan compared to other angiotensin receptor blockersDevices in the management of advanced, chronic heart failureStandards of medical care in diabetes--2012Critical Questions about PARADIGM-HF and the FutureHeart Failure: Diagnosis, Management and UtilizationReducing cardiorenal risk through combination therapy with a direct renin inhibitorTelmisartan and cardioprotectionStructural basis for telmisartan-mediated partial activation of PPAR gammaHeart Failure: a Major Cardiovascular Complication of Diabetes MellitusPresent and future pharmacotherapeutic agents in heart failure: an evolving paradigmClinical trials update from the European Society of Cardiology: CHARM, BASEL, EUROPA and ESTEEMThe 2006 Canadian Hypertension Education Program recommendations for the management of hypertension: Part II - TherapyRole of angiotensin II in cardiovascular disease therapeutic implications of more than a century of researchLong-term use of secondary prevention medications for heart failure in Western Australia: a protocol for a population-based cohort studyMeta-analysis of combined therapy with angiotensin receptor antagonists versus ACE inhibitors alone in patients with heart failureManagement of end-stage heart failure: a perspective on the Arab Gulf statesStandards of medical care in diabetes--2013Novel Cardiac Intracrine Mechanisms Based on Ang-(1-12)/Chymase Axis Require a Revision of Therapeutic Approaches in Human Heart Disease.Thirty Years of Evidence on the Efficacy of Drug Treatments for Chronic Heart Failure With Reduced Ejection Fraction: A Network Meta-AnalysisMedical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer.Comparing angiotensin II receptor blockers on benefits beyond blood pressureRAAS inhibitors and cardiovascular protection in large scale trials.A current evaluation of the safety of angiotensin receptor blockers and direct renin inhibitorsDifferential effects of late-life initiation of low-dose enalapril and losartan on diastolic function in senescent Fischer 344 x Brown Norway male rats.Rationale for combining a direct renin inhibitor with other renin- angiotensin system blockers. Focus on aliskiren and combinations.Angioedema related to Angiotensin inhibitors.Aliskiren: review of efficacy and safety data with focus on past and recent clinical trials.Multidrug and optimal heart failure therapy prescribing in older general practice populations: a clinical data linkage study.Prevalence of guideline-directed medical therapy among patients receiving cardiac resynchronization therapy defibrillator implantation in the National Cardiovascular Data Registry during the years 2006 to 2008.More evidence on blocking the renin-angiotensin-aldosterone system in cardiovascular disease and the long-term treatment of hypertension: data from recent clinical trials (CHARM, EUROPA, ValHEFT, HOPE-TOO and SYST-EUR2).Prognosis and mechanism of death in treated heart failure: data from the placebo arm of Val-HeFT.Renal dysfunction, restrictive left ventricular filling pattern and mortality risk in patients admitted with heart failure: a 7-year follow-up studyLiver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) programCardiovascular outcomes in high-risk patients without heart failure treated with ARBs: a systematic review and meta-analysis.Efficacy in angiotensin receptor blockade: a comparative review of data with olmesartan.Standards of medical care in diabetes--2010.Management of hypertension with fixed dose combinations of candesartan cilexetil and hydrochlorothiazide: patient perspectives and clinical utility
P2860
Q24199125-39FA036B-772C-4376-84A6-51BC93EB7538Q24234511-CC14A6D5-E4EB-42D9-AB5E-F9A19E9D1493Q24241097-BEBA67FC-F42A-4B46-9C4B-A96091A172C1Q24613321-21EA34E3-0B99-4DAA-83A9-8B2862465434Q24630052-E9C8B05F-8C49-47BE-86E7-4B09A5FC96C3Q24632533-DD6334AE-7C98-4289-9660-0ED81668437EQ26741029-5F0238F3-6403-4A51-A09C-0321E9C8E6F3Q26745543-31678470-7BE7-4E28-AA78-6D8BDDBC24AEQ26851307-1B653264-68D4-4C8B-9270-CDC35AE8624BQ26861422-8D3958F3-9931-485B-999A-763A27B83692Q27677426-A887D6FB-C6A1-4718-A1FC-78BABD9403C6Q28066310-39A34474-5AC6-4763-B932-716055D2F47DQ28077186-25E83C20-CDD8-4127-BC4D-7B2D20EF8DEFQ28166022-0C5582FA-7FB4-460A-A404-3E4A99EEC8E2Q28218811-E1440CDC-8AAD-4F73-B388-DE63864B1511Q28272171-9DCEBD3A-5DF7-48F4-A7BB-F2AE38EE2D20Q28591667-8BDEE138-24E4-4042-8D9D-AD89DF6D479EQ28748219-17BB0EA1-7685-4F27-8D81-3DC7D89B6B0CQ28751716-2B06BFD9-60BF-48DC-B8BD-0424396263BFQ29620309-436EAEE4-53A7-4D89-9E68-3EF3AACF01E7Q30235583-734815C8-23BA-41B6-8B12-553A58D1BF74Q30239022-E9C684A9-E3BE-4A8E-BD0B-64FA8A2029CEQ30248340-E0D6E577-EACA-4DFE-A620-F286294A3732Q30360678-CAACD72A-0D85-40CD-AB02-7A96952701AAQ30424541-23EB0BF4-425B-425F-BA94-CBA1274B3E7DQ30432209-49BA063A-6D3F-4ADB-9E26-D6C883BAAF03Q30451313-3DEFE325-F903-4A34-A1F9-115838102DECQ30452640-F264D0D7-3CE4-44AF-8234-2EA1B1908A02Q30458886-7DA4FF0C-639E-4391-8BBD-BFF5512122F8Q30664624-7740F82C-A148-4E56-AF28-8CEFB9A01397Q30725233-8081F044-2992-4C09-8985-873229DF37CDQ30813903-30622C36-5963-4FEF-B04C-3E0B9889BAA3Q30882854-263BDCAD-19B6-45C3-AF39-2EF76BB0E74CQ31043636-BBF210A0-B908-4B5F-B166-895C5B570098Q31145367-8CDBD8E5-5DD6-44D9-8083-F118A2FE17C4Q33402824-4CA6E688-8257-4F7C-A309-D4097723E9F9Q33403831-A624CEA6-6C00-4E44-AEA7-7B8FF5149A3BQ33490031-666567FB-B4D5-4521-80E6-0E37F644852BQ33554238-78A07CB6-9CBE-4BCE-B677-039D9853FCFCQ33571219-05487F54-D160-4217-8493-E5CDC0CD00FB
P2860
Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial.
description
2003 nî lūn-bûn
@nan
2003 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
name
Effects of candesartan in pati ...... bitors: the CHARM-Added trial.
@ast
Effects of candesartan in pati ...... bitors: the CHARM-Added trial.
@en
Effects of candesartan in pati ...... bitors: the CHARM-Added trial.
@nl
type
label
Effects of candesartan in pati ...... bitors: the CHARM-Added trial.
@ast
Effects of candesartan in pati ...... bitors: the CHARM-Added trial.
@en
Effects of candesartan in pati ...... bitors: the CHARM-Added trial.
@nl
prefLabel
Effects of candesartan in pati ...... bitors: the CHARM-Added trial.
@ast
Effects of candesartan in pati ...... bitors: the CHARM-Added trial.
@en
Effects of candesartan in pati ...... bitors: the CHARM-Added trial.
@nl
P2093
P50
P921
P1433
P1476
Effects of candesartan in pati ...... bitors: the CHARM-Added trial.
@en
P2093
Bertil Olofsson
CHARM Investigators and Committees
Eric L Michelson
Jan Ostergren
John J V McMurray
Marc A Pfeffer
Peter Held
P304
P356
10.1016/S0140-6736(03)14283-3
P407
P577
2003-09-01T00:00:00Z